Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.

Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research18 Jul 2005Cited by 130 (Europe PMC)

PMID16234962DOI10.1359/jbmr.050714PepBankPUB-16234962

Source link PubMedAsk about this study

Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide alone increased lumbar spine BMD 5.19% from baseline.
In plain wordsIn women with osteoporosis, teriparatide alone increased spine bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD with teriparatide alone
Study
n = 68
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Lumbar spine BMD change
5.19%
teriparatide alone versus baseline
Source sentences
Summary
Lumbar spine BMD significantly increased 5.19 +/- 0.67% from baseline in the teriparatide-alone group.
1 context sentence(design, population, supporting numbers)
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
Report a problemFND-1623496204
02HumanRandomized controlled trialSafety outcome
In women with osteoporosis, teriparatide alone increased mean serum calcium by 0.30 mg/dl from baseline.
In plain wordsIn women with osteoporosis, teriparatide alone increased blood calcium from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum calcium with teriparatide alone
Study
n = 68
Comparator
Baseline
Outcome group
Adverse events · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Serum calcium change
0.3 mg/dl
teriparatide alone versus baseline
Source sentences
Summary
In the teriparatide-alone group, mean serum calcium levels increased from baseline to endpoint (0.30 +/- 0.06 mg/dl, p < 0.001), whereas mean serum phosphate remained unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
Report a problemFND-1623496209
03HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, serum phosphate remained unchanged with teriparatide alone.
In plain wordsIn women with osteoporosis, blood phosphate remained unchanged with teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum phosphate with teriparatide alone
Study
n = 68
Comparator
Baseline
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
In the teriparatide-alone group, mean serum calcium levels increased from baseline to endpoint (0.30 +/- 0.06 mg/dl, p < 0.001), whereas mean serum phosphate remained unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
Report a problemFND-1623496210
04HumanRandomized controlled trialMechanism
In women with osteoporosis, serum CTx increased during teriparatide monotherapy.
In plain wordsIn women with osteoporosis, a bone breakdown marker increased during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCTx increase with teriparatide monotherapy
Study
n = 68
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
However, the increase in bone resorption (serum C-terminal telopeptide of type I collagen [CTx]) in the combination group was significantly smaller than in the teriparatide-alone group (p = 0.015).
1 context sentence(design, population, supporting numbers)
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
Report a problemFND-1623496216

Studies that did not test the peptide alone12

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide plus raloxifene produced a smaller CTx increase than teriparatide alone.
In plain wordsIn women with osteoporosis, teriparatide plus raloxifene increased bone resorption less than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCTx increase with combination versus monotherapy
Study
n = 137
Comparator
Teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
However, the increase in bone resorption (serum C-terminal telopeptide of type I collagen [CTx]) in the combination group was significantly smaller than in the teriparatide-alone group (p = 0.015).
1 context sentence(design, population, supporting numbers)
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1623496203
06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide plus raloxifene increased total hip BMD more than teriparatide alone.
In plain wordsIn women with osteoporosis, teriparatide plus raloxifene increased hip bone density more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD increase versus monotherapy
Study
n = 137
Comparator
Teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the combination group, lumbar spine (6.19 +/- 0.65%), femoral neck (2.23 +/- 0.64%), and total hip (2.31 +/- 0.56%) BMD significantly increased from baseline to study endpoint, and the increase in total hip BMD was significantly greater than in the teriparatide-alone group (p = 0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1623496208
07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, serum calcium rose less with teriparatide plus raloxifene than with teriparatide alone.
In plain wordsIn women with osteoporosis, blood calcium rose less with teriparatide plus raloxifene than with teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum calcium change versus monotherapy
Study
n = 137
Comparator
Teriparatide alone
Outcome group
Bone and joint · Endocrine and hormones
Source sentences
Summary
Changes in serum calcium (p < 0.001) and phosphate (p < 0.004) were significantly different between treatment groups.
3 context sentences(design, population, supporting numbers)
Summary · context
In the teriparatide-alone group, mean serum calcium levels increased from baseline to endpoint (0.30 +/- 0.06 mg/dl, p < 0.001), whereas mean serum phosphate remained unchanged.
Summary · context
In the combination group, mean serum calcium was unchanged, and mean serum phosphate decreased (-0.20 +/- 0.06 mg/dl, p < 0.001) from baseline to endpoint.
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1623496213
08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, serum phosphate decreased more with teriparatide plus raloxifene than with teriparatide alone.
In plain wordsIn women with osteoporosis, blood phosphate decreased more with teriparatide plus raloxifene than with teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum phosphate change versus monotherapy
Study
n = 137
Comparator
Teriparatide alone
Outcome group
Bone and joint · Endocrine and hormones
Source sentences
Summary
Changes in serum calcium (p < 0.001) and phosphate (p < 0.004) were significantly different between treatment groups.
3 context sentences(design, population, supporting numbers)
Summary · context
In the teriparatide-alone group, mean serum calcium levels increased from baseline to endpoint (0.30 +/- 0.06 mg/dl, p < 0.001), whereas mean serum phosphate remained unchanged.
Summary · context
In the combination group, mean serum calcium was unchanged, and mean serum phosphate decreased (-0.20 +/- 0.06 mg/dl, p < 0.001) from baseline to endpoint.
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1623496214
09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialSafety outcome
In women with osteoporosis, teriparatide plus raloxifene had a safety profile similar to teriparatide alone.
In plain wordsIn women with osteoporosis, teriparatide plus raloxifene had similar safety to teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeOverall safety profile
Study
n = 137
Comparator
Teriparatide alone
Outcome group
Adverse events · Whole body
Source sentences
Summary
The safety profile of combination therapy was similar to teriparatide alone.
1 context sentence(design, population, supporting numbers)
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1623496215
10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide plus raloxifene increased PINP similarly to teriparatide alone.
In plain wordsIn women with osteoporosis, teriparatide plus raloxifene increased a bone formation marker similarly to teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePINP with combination therapy
Study
n = 69
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Bone formation (N-terminal propeptide of type 1 collagen [PINP]) increased similarly in both treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1623496202
11HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide plus raloxifene increased lumbar spine BMD 6.19% from baseline.
In plain wordsIn women with osteoporosis, teriparatide plus raloxifene increased spine bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD with combination therapy
Study
n = 69
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Lumbar spine BMD change
6.19%
combination versus baseline
Source sentences
Summary
In the combination group, lumbar spine (6.19 +/- 0.65%), femoral neck (2.23 +/- 0.64%), and total hip (2.31 +/- 0.56%) BMD significantly increased from baseline to study endpoint, and the increase in total hip BMD was significantly greater than in the teriparatide-alone group (p = 0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1623496205
12HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide plus raloxifene increased femoral neck BMD 2.23% from baseline.
In plain wordsIn women with osteoporosis, teriparatide plus raloxifene increased femoral neck bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD with combination therapy
Study
n = 69
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Femoral neck BMD change
2.23%
combination versus baseline
Source sentences
Summary
In the combination group, lumbar spine (6.19 +/- 0.65%), femoral neck (2.23 +/- 0.64%), and total hip (2.31 +/- 0.56%) BMD significantly increased from baseline to study endpoint, and the increase in total hip BMD was significantly greater than in the teriparatide-alone group (p = 0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1623496206
13HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide plus raloxifene increased total hip BMD 2.31% from baseline.
In plain wordsIn women with osteoporosis, teriparatide plus raloxifene increased total hip bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD with combination therapy
Study
n = 69
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total hip BMD change
2.31%
combination versus baseline
Source sentences
Summary
In the combination group, lumbar spine (6.19 +/- 0.65%), femoral neck (2.23 +/- 0.64%), and total hip (2.31 +/- 0.56%) BMD significantly increased from baseline to study endpoint, and the increase in total hip BMD was significantly greater than in the teriparatide-alone group (p = 0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1623496207
14HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialSafety outcome
In women with osteoporosis, serum calcium remained unchanged with teriparatide plus raloxifene.
In plain wordsIn women with osteoporosis, blood calcium remained unchanged with teriparatide plus raloxifene.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum calcium with combination therapy
Study
n = 69
Comparator
Baseline
Outcome group
Adverse events · Endocrine and hormones
Source sentences
Summary
In the combination group, mean serum calcium was unchanged, and mean serum phosphate decreased (-0.20 +/- 0.06 mg/dl, p < 0.001) from baseline to endpoint.
1 context sentence(design, population, supporting numbers)
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1623496211
15HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide plus raloxifene decreased serum phosphate by 0.20 mg/dl from baseline.
In plain wordsIn women with osteoporosis, teriparatide plus raloxifene decreased blood phosphate from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum phosphate with combination therapy
Study
n = 69
Comparator
Baseline
Outcome group
Bone and joint · Endocrine and hormones
Measurements
Serum phosphate change
−0.2 mg/dl
combination versus baseline
Source sentences
Summary
In the combination group, mean serum calcium was unchanged, and mean serum phosphate decreased (-0.20 +/- 0.06 mg/dl, p < 0.001) from baseline to endpoint.
1 context sentence(design, population, supporting numbers)
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1623496212
16HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, PINP increased with teriparatide alone, similarly to combination therapy.
In plain wordsIn women with osteoporosis, teriparatide alone increased a bone formation marker similarly to combination therapy.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePINP with teriparatide alone
Study
n = 68
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Bone formation (N-terminal propeptide of type 1 collagen [PINP]) increased similarly in both treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1623496201

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.